PubMed:15464247 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"1129","span":{"begin":13,"end":28},"obj":"GeneOrGeneProduct"},{"id":"1130","span":{"begin":30,"end":35},"obj":"GeneOrGeneProduct"},{"id":"1131","span":{"begin":102,"end":129},"obj":"DiseaseOrPhenotypicFeature"},{"id":"1132","span":{"begin":148,"end":162},"obj":"GeneOrGeneProduct"},{"id":"1133","span":{"begin":164,"end":169},"obj":"GeneOrGeneProduct"},{"id":"1134","span":{"begin":271,"end":284},"obj":"DiseaseOrPhenotypicFeature"},{"id":"1135","span":{"begin":314,"end":319},"obj":"GeneOrGeneProduct"},{"id":"1136","span":{"begin":362,"end":385},"obj":"SequenceVariant"},{"id":"1137","span":{"begin":403,"end":411},"obj":"SequenceVariant"},{"id":"1138","span":{"begin":452,"end":457},"obj":"GeneOrGeneProduct"},{"id":"1139","span":{"begin":504,"end":517},"obj":"DiseaseOrPhenotypicFeature"},{"id":"1140","span":{"begin":573,"end":576},"obj":"OrganismTaxon"},{"id":"1141","span":{"begin":604,"end":616},"obj":"DiseaseOrPhenotypicFeature"},{"id":"1142","span":{"begin":617,"end":625},"obj":"OrganismTaxon"},{"id":"1143","span":{"begin":653,"end":658},"obj":"GeneOrGeneProduct"},{"id":"1144","span":{"begin":748,"end":763},"obj":"ChemicalEntity"},{"id":"1145","span":{"begin":861,"end":866},"obj":"GeneOrGeneProduct"},{"id":"1146","span":{"begin":966,"end":989},"obj":"DiseaseOrPhenotypicFeature"},{"id":"1147","span":{"begin":990,"end":998},"obj":"OrganismTaxon"},{"id":"1148","span":{"begin":1018,"end":1025},"obj":"DiseaseOrPhenotypicFeature"},{"id":"1149","span":{"begin":1039,"end":1044},"obj":"GeneOrGeneProduct"},{"id":"1150","span":{"begin":1052,"end":1058},"obj":"SequenceVariant"},{"id":"1151","span":{"begin":1273,"end":1278},"obj":"GeneOrGeneProduct"},{"id":"1152","span":{"begin":1286,"end":1292},"obj":"SequenceVariant"},{"id":"1153","span":{"begin":1456,"end":1461},"obj":"GeneOrGeneProduct"},{"id":"1154","span":{"begin":1493,"end":1506},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"db_id","subj":"1129","obj":"NCBIGene:3593"},{"id":"A2","pred":"db_id","subj":"1130","obj":"NCBIGene:3593"},{"id":"A3","pred":"db_id","subj":"1131","obj":"MESH:D006526"},{"id":"A4","pred":"db_id","subj":"1132","obj":"NCBIGene:3593"},{"id":"A5","pred":"db_id","subj":"1133","obj":"NCBIGene:3593"},{"id":"A6","pred":"db_id","subj":"1134","obj":"MESH:D006526"},{"id":"A7","pred":"db_id","subj":"1135","obj":"NCBIGene:3593"},{"id":"A8","pred":"db_id","subj":"1136","obj":"c|INDEL||4"},{"id":"A9","pred":"db_id","subj":"1137","obj":"c|SUB|A|1188|C"},{"id":"A10","pred":"db_id","subj":"1138","obj":"NCBIGene:3593"},{"id":"A11","pred":"db_id","subj":"1139","obj":"MESH:D006526"},{"id":"A12","pred":"db_id","subj":"1140","obj":"NCBITaxon:11103"},{"id":"A13","pred":"db_id","subj":"1141","obj":"MESH:D006526"},{"id":"A14","pred":"db_id","subj":"1142","obj":"NCBITaxon:9606"},{"id":"A15","pred":"db_id","subj":"1143","obj":"NCBIGene:3593"},{"id":"A16","pred":"db_id","subj":"1144","obj":"MESH:D009841"},{"id":"A17","pred":"db_id","subj":"1145","obj":"NCBIGene:3593"},{"id":"A18","pred":"db_id","subj":"1146","obj":"MESH:D006526"},{"id":"A19","pred":"db_id","subj":"1147","obj":"NCBITaxon:9606"},{"id":"A20","pred":"db_id","subj":"1148","obj":"MESH:D014766"},{"id":"A21","pred":"db_id","subj":"1149","obj":"NCBIGene:3593"},{"id":"A22","pred":"db_id","subj":"1150","obj":"c|Allele|C|1188"},{"id":"A23","pred":"db_id","subj":"1151","obj":"NCBIGene:3593"},{"id":"A24","pred":"db_id","subj":"1152","obj":"c|Allele|C|1188"},{"id":"A25","pred":"db_id","subj":"1153","obj":"NCBIGene:3593"},{"id":"A26","pred":"db_id","subj":"1154","obj":"MESH:D006526"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":130},"obj":"Sentence"},{"id":"T2","span":{"begin":131,"end":147},"obj":"Sentence"},{"id":"T3","span":{"begin":148,"end":285},"obj":"Sentence"},{"id":"T4","span":{"begin":286,"end":518},"obj":"Sentence"},{"id":"T5","span":{"begin":519,"end":527},"obj":"Sentence"},{"id":"T6","span":{"begin":528,"end":652},"obj":"Sentence"},{"id":"T7","span":{"begin":653,"end":833},"obj":"Sentence"},{"id":"T8","span":{"begin":834,"end":842},"obj":"Sentence"},{"id":"T9","span":{"begin":843,"end":956},"obj":"Sentence"},{"id":"T10","span":{"begin":957,"end":1259},"obj":"Sentence"},{"id":"T11","span":{"begin":1260,"end":1437},"obj":"Sentence"},{"id":"T12","span":{"begin":1438,"end":1529},"obj":"Sentence"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T1","span":{"begin":102,"end":119},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":271,"end":274},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":504,"end":507},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":573,"end":576},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":604,"end":607},"obj":"OrganismTaxon"},{"id":"T6","span":{"begin":966,"end":969},"obj":"OrganismTaxon"},{"id":"T7","span":{"begin":1493,"end":1496},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"NCBItxid:11103"},{"id":"A2","pred":"db_id","subj":"T2","obj":"NCBItxid:11103"},{"id":"A3","pred":"db_id","subj":"T3","obj":"NCBItxid:11103"},{"id":"A4","pred":"db_id","subj":"T4","obj":"NCBItxid:11103"},{"id":"A5","pred":"db_id","subj":"T5","obj":"NCBItxid:11103"},{"id":"A6","pred":"db_id","subj":"T6","obj":"NCBItxid:11103"},{"id":"A7","pred":"db_id","subj":"T7","obj":"NCBItxid:11103"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":102,"end":129},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":102,"end":111},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005231"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0002251"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-SeqVar","denotations":[{"id":"T1","span":{"begin":25,"end":28},"obj":"SequenceVariant"},{"id":"T2","span":{"begin":362,"end":376},"obj":"SequenceVariant"},{"id":"T3","span":{"begin":403,"end":411},"obj":"SequenceVariant"},{"id":"T4","span":{"begin":1052,"end":1058},"obj":"SequenceVariant"},{"id":"T5","span":{"begin":1286,"end":1292},"obj":"SequenceVariant"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T1","span":{"begin":13,"end":28},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":30,"end":35},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":80,"end":87},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":148,"end":162},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":164,"end":169},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":183,"end":186},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":192,"end":198},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":249,"end":256},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":314,"end":319},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":395,"end":401},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":452,"end":457},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":519,"end":526},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":588,"end":591},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":653,"end":658},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":659,"end":665},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":714,"end":719},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":779,"end":784},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":861,"end":866},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":880,"end":886},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":1004,"end":1008},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":1039,"end":1044},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":1045,"end":1051},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":1164,"end":1170},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":1189,"end":1196},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":1241,"end":1247},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":1273,"end":1278},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":1279,"end":1285},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":1300,"end":1308},"obj":"GeneOrGeneProduct"},{"id":"T29","span":{"begin":1322,"end":1329},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":1416,"end":1423},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":1456,"end":1461},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":1485,"end":1492},"obj":"GeneOrGeneProduct"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T1","span":{"begin":13,"end":28},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":30,"end":35},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":148,"end":162},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":164,"end":169},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":314,"end":319},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":395,"end":401},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":452,"end":457},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":588,"end":591},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":653,"end":658},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":659,"end":665},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":861,"end":866},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":880,"end":886},"obj":"GeneOrGeneProduct"},{"id":"T13","span":{"begin":1004,"end":1008},"obj":"GeneOrGeneProduct"},{"id":"T14","span":{"begin":1039,"end":1044},"obj":"GeneOrGeneProduct"},{"id":"T15","span":{"begin":1045,"end":1051},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":1189,"end":1196},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":1273,"end":1278},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":1279,"end":1285},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":1416,"end":1423},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":1456,"end":1461},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":1485,"end":1492},"obj":"GeneOrGeneProduct"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T1","span":{"begin":102,"end":113},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":114,"end":129},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":275,"end":284},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":508,"end":517},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":1018,"end":1025},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1197,"end":1204},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1424,"end":1431},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1497,"end":1506},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A8","pred":"originalLabel","subj":"T8","obj":"D007239"},{"id":"A2","pred":"originalLabel","subj":"T2","obj":"D014777"},{"id":"A4","pred":"originalLabel","subj":"T4","obj":"D007239"},{"id":"A7","pred":"originalLabel","subj":"T7","obj":"D012008"},{"id":"A1","pred":"originalLabel","subj":"T1","obj":"D006526"},{"id":"A5","pred":"originalLabel","subj":"T5","obj":"D014766"},{"id":"A3","pred":"originalLabel","subj":"T3","obj":"D007239"},{"id":"A6","pred":"originalLabel","subj":"T6","obj":"D012008"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T1","span":{"begin":13,"end":28},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":30,"end":35},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":148,"end":162},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":164,"end":169},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":314,"end":319},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":452,"end":457},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":588,"end":591},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":653,"end":658},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":861,"end":866},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":1039,"end":1044},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":1273,"end":1278},"obj":"GeneOrGeneProduct"},{"id":"T12","span":{"begin":1456,"end":1461},"obj":"GeneOrGeneProduct"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T1","span":{"begin":102,"end":129},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":275,"end":284},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":508,"end":517},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":1497,"end":1506},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005231"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0005550"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005550"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0005550"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T1","span":{"begin":102,"end":113},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":114,"end":129},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":275,"end":284},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":508,"end":517},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":604,"end":616},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":966,"end":989},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1018,"end":1025},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1197,"end":1204},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":1424,"end":1431},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":1497,"end":1506},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A10","pred":"ID:","subj":"T10","obj":"D007239"},{"id":"A9","pred":"ID:","subj":"T9","obj":"D012008"},{"id":"A1","pred":"ID:","subj":"T1","obj":"D006526"},{"id":"A8","pred":"ID:","subj":"T8","obj":"D012008"},{"id":"A5","pred":"ID:","subj":"T5","obj":"DISEASE"},{"id":"A6","pred":"ID:","subj":"T6","obj":"DISEASE"},{"id":"A2","pred":"ID:","subj":"T2","obj":"D014777"},{"id":"A3","pred":"ID:","subj":"T3","obj":"D007239"},{"id":"A4","pred":"ID:","subj":"T4","obj":"D007239"},{"id":"A7","pred":"ID:","subj":"T7","obj":"D014766"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T1","span":{"begin":102,"end":113},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":271,"end":284},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":504,"end":517},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":604,"end":616},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":966,"end":989},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":1018,"end":1025},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1493,"end":1506},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"#label","subj":"T1","obj":"D006526"},{"id":"A2","pred":"#label","subj":"T2","obj":"Eisukeadded"},{"id":"A3","pred":"#label","subj":"T3","obj":"Eisukeadded"},{"id":"A4","pred":"#label","subj":"T4","obj":"DISEASE"},{"id":"A5","pred":"#label","subj":"T5","obj":"DISEASE"},{"id":"A6","pred":"#label","subj":"T6","obj":"D014766"},{"id":"A7","pred":"#label","subj":"T7","obj":"Eisukeadded"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T1","span":{"begin":102,"end":119},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":271,"end":274},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":504,"end":507},"obj":"OrganismTaxon"},{"id":"T4","span":{"begin":573,"end":576},"obj":"OrganismTaxon"},{"id":"T5","span":{"begin":604,"end":607},"obj":"OrganismTaxon"},{"id":"T6","span":{"begin":617,"end":625},"obj":"OrganismTaxon"},{"id":"T7","span":{"begin":966,"end":969},"obj":"OrganismTaxon"},{"id":"T8","span":{"begin":990,"end":998},"obj":"OrganismTaxon"},{"id":"T9","span":{"begin":1493,"end":1496},"obj":"OrganismTaxon"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T12","span":{"begin":1456,"end":1461},"obj":"GeneOrGeneProduct"},{"id":"T11","span":{"begin":1273,"end":1278},"obj":"GeneOrGeneProduct"},{"id":"T10","span":{"begin":1039,"end":1044},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":861,"end":866},"obj":"GeneOrGeneProduct"},{"id":"T8","span":{"begin":653,"end":658},"obj":"GeneOrGeneProduct"},{"id":"T7","span":{"begin":588,"end":591},"obj":"GeneOrGeneProduct"},{"id":"T6","span":{"begin":452,"end":457},"obj":"GeneOrGeneProduct"},{"id":"T5","span":{"begin":314,"end":319},"obj":"GeneOrGeneProduct"},{"id":"T4","span":{"begin":164,"end":169},"obj":"GeneOrGeneProduct"},{"id":"T3","span":{"begin":148,"end":162},"obj":"GeneOrGeneProduct"},{"id":"T2","span":{"begin":30,"end":35},"obj":"GeneOrGeneProduct"},{"id":"T1","span":{"begin":13,"end":28},"obj":"GeneOrGeneProduct"},{"id":"T39418","span":{"begin":1493,"end":1506},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T69592","span":{"begin":1018,"end":1025},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T37045","span":{"begin":966,"end":989},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2531","span":{"begin":604,"end":616},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T22052","span":{"begin":504,"end":517},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T61718","span":{"begin":271,"end":284},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T93260","span":{"begin":102,"end":113},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T54801","span":{"begin":1493,"end":1496},"obj":"OrganismTaxon"},{"id":"T72728","span":{"begin":990,"end":998},"obj":"OrganismTaxon"},{"id":"T96562","span":{"begin":966,"end":969},"obj":"OrganismTaxon"},{"id":"T81224","span":{"begin":617,"end":625},"obj":"OrganismTaxon"},{"id":"T91168","span":{"begin":604,"end":607},"obj":"OrganismTaxon"},{"id":"T34462","span":{"begin":573,"end":576},"obj":"OrganismTaxon"},{"id":"T68858","span":{"begin":504,"end":507},"obj":"OrganismTaxon"},{"id":"T20395","span":{"begin":271,"end":274},"obj":"OrganismTaxon"},{"id":"T29972","span":{"begin":102,"end":119},"obj":"OrganismTaxon"},{"id":"T10897","span":{"begin":1286,"end":1292},"obj":"SequenceVariant"},{"id":"T75229","span":{"begin":1052,"end":1058},"obj":"SequenceVariant"},{"id":"T1192","span":{"begin":403,"end":411},"obj":"SequenceVariant"},{"id":"T17743","span":{"begin":362,"end":376},"obj":"SequenceVariant"},{"id":"T81210","span":{"begin":25,"end":28},"obj":"SequenceVariant"}],"attributes":[{"id":"A7","pred":"#label","subj":"T39418","obj":"Eisukeadded"},{"id":"A6","pred":"#label","subj":"T69592","obj":"D014766"},{"id":"A5","pred":"#label","subj":"T37045","obj":"DISEASE"},{"id":"A4","pred":"#label","subj":"T2531","obj":"DISEASE"},{"id":"A3","pred":"#label","subj":"T22052","obj":"Eisukeadded"},{"id":"A2","pred":"#label","subj":"T61718","obj":"Eisukeadded"},{"id":"A1","pred":"#label","subj":"T93260","obj":"D006526"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"15464247-0#13#28#gene3593","span":{"begin":13,"end":28},"obj":"gene3593"},{"id":"15464247-0#30#35#gene3593","span":{"begin":30,"end":35},"obj":"gene3593"},{"id":"15464247-0#102#113#diseaseC0019196","span":{"begin":102,"end":113},"obj":"diseaseC0019196"},{"id":"15464247-0#114#129#diseaseC0042769","span":{"begin":114,"end":129},"obj":"diseaseC0042769"},{"id":"15464247-0#102#113#diseaseC0019196","span":{"begin":102,"end":113},"obj":"diseaseC0019196"},{"id":"15464247-0#114#129#diseaseC0042769","span":{"begin":114,"end":129},"obj":"diseaseC0042769"}],"relations":[{"id":"13#28#gene3593102#113#diseaseC0019196","pred":"associated_with","subj":"15464247-0#13#28#gene3593","obj":"15464247-0#102#113#diseaseC0019196"},{"id":"13#28#gene3593114#129#diseaseC0042769","pred":"associated_with","subj":"15464247-0#13#28#gene3593","obj":"15464247-0#114#129#diseaseC0042769"},{"id":"13#28#gene3593102#113#diseaseC0019196","pred":"associated_with","subj":"15464247-0#13#28#gene3593","obj":"15464247-0#102#113#diseaseC0019196"},{"id":"13#28#gene3593114#129#diseaseC0042769","pred":"associated_with","subj":"15464247-0#13#28#gene3593","obj":"15464247-0#114#129#diseaseC0042769"},{"id":"30#35#gene3593102#113#diseaseC0019196","pred":"associated_with","subj":"15464247-0#30#35#gene3593","obj":"15464247-0#102#113#diseaseC0019196"},{"id":"30#35#gene3593114#129#diseaseC0042769","pred":"associated_with","subj":"15464247-0#30#35#gene3593","obj":"15464247-0#114#129#diseaseC0042769"},{"id":"30#35#gene3593102#113#diseaseC0019196","pred":"associated_with","subj":"15464247-0#30#35#gene3593","obj":"15464247-0#102#113#diseaseC0019196"},{"id":"30#35#gene3593114#129#diseaseC0042769","pred":"associated_with","subj":"15464247-0#30#35#gene3593","obj":"15464247-0#114#129#diseaseC0042769"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"tmVarCorpus","denotations":[{"id":"T1","span":{"begin":403,"end":411},"obj":"DNAMutation:g|SUB|A|1188|C"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":13,"end":28},"obj":"gene:3593"},{"id":"T1","span":{"begin":102,"end":113},"obj":"disease:C0019196"},{"id":"T2","span":{"begin":13,"end":28},"obj":"gene:3593"},{"id":"T3","span":{"begin":114,"end":129},"obj":"disease:C0042769"},{"id":"T4","span":{"begin":30,"end":35},"obj":"gene:3593"},{"id":"T5","span":{"begin":102,"end":113},"obj":"disease:C0019196"},{"id":"T6","span":{"begin":30,"end":35},"obj":"gene:3593"},{"id":"T7","span":{"begin":114,"end":129},"obj":"disease:C0042769"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"},{"id":"R3","pred":"associated_with","subj":"T4","obj":"T5"},{"id":"R4","pred":"associated_with","subj":"T6","obj":"T7"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection.\nBACKGROUND/AIMS: Interleukin-12 (IL-12) governs the Th1-type immune response, affecting the spontaneous and treatment-induced recovery from HCV-infection. We investigated whether the IL12B polymorphisms within the promoter region (4 bp insertion/deletion) and the 3'-UTR (1188-A/C), which have been reported to influence IL-12 synthesis, are associated with the outcome of HCV infection.\nMETHODS: We analyzed 186 individuals with spontaneous HCV clearance, 501 chronically HCV infected patients, and 217 healthy controls. IL12B 3'-UTR and promoter genotyping was performed by Taqman-based assays with allele-specific oligonucleotide probes and PCR-based allele-specific DNA-amplification, respectively.\nRESULTS: The proportion of IL12B promoter and 3'-UTR genotypes did not differ significantly between the different cohorts. However, HCV genotype 1-infected patients with high baseline viremia carrying the IL12B 3'-UTR 1188-C-allele showed significantly higher sustained virologic response (SVR) rates (25.3% vs. 46% vs. 54.5% for A/A, A/C and C/C) due to reduced relapse rates (24.2% vs. 12% vs. zero % for A/A, A/C and C/C).\nCONCLUSIONS: IL12B 3'-UTR 1188-C-allele carriers appear to be capable of responding more efficiently to antiviral combination therapy as a consequence of a reduced relapse rate. No association of IL12B polymorphisms and self-limited HCV infection could be demonstrated."}